about
IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon inductionDNA vaccines: a simple DNA sensing matter?Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6TRAF4 acts as a silencer in TLR-mediated signaling through the association with TRAF6 and TRIFHydroxypropyl-β-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen.Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist.Serologic markers in relation to parasite exposure history help to estimate transmission dynamics of Plasmodium vivax.The origins of African Plasmodium vivax; insights from mitochondrial genome sequencingPurified malaria pigment (hemozoin) enhances dendritic cell maturation and modulates the isotype of antibodies induced by a DNA vaccineLimited polymorphism of the Plasmodium vivax merozoite surface protein 1 gene in isolates from TurkeyThe chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant.Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity.Host innate immune receptors and beyond: making sense of microbial infections.Evidence for the transmission of Plasmodium vivax in the Republic of the Congo, West Central Africa.Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use.Essential role of IPS-1 in innate immune responses against RNA viruses.Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.Manifold mechanisms of Toll-like receptor-ligand recognition.Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects.Manipulation of host innate immune responses by the malaria parasite.RNA is an Adjuvanticity Mediator for the Lipid-Based Mucosal Adjuvant, EndocineInnate immune response to viral infection.TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.Innate immune control of nucleic acid-based vaccine immunogenicity.Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines.Immune interventions of human diseases through toll-like receptors.Bacterial secretion system skews the fate of Legionella-containing vacuoles towards LC3-associated phagocytosis.The malarial metabolite hemozoin and its potential use as a vaccine adjuvant.TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine.Novel strategies to improve DNA vaccine immunogenicity.Current status of synthetic hemozoin adjuvant: A preliminary safety evaluation.Experimental cerebral malaria progresses independently of the Nlrp3 inflammasome.Olfactory plays a key role in spatiotemporal pathogenesis of cerebral malaria.Plasmodium products persist in the bone marrow and promote chronic bone loss.Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets.Synthesis and in vitro characterization of antigen-conjugated polysaccharide as a CpG DNA carrier.Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors.Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction.
P50
Q24318426-AB6C8453-0FF1-4EBE-90B3-E21B4AEEAABCQ26859016-C18E9348-5F1D-466B-AD6E-88D4EA684EB6Q28115232-05443F74-FC1D-435C-8EBC-8737E8FFE4D3Q28264410-9AE4D9F4-0085-4B7A-B159-C219C996AD8BQ30371719-B7D4124D-EC58-4C04-89EF-B1B06B5899A2Q30573156-6D4FA045-4BA0-490E-94BF-66B45041691EQ34091277-F3BF4C10-7C94-4ED7-80B0-2B82354C22A6Q34110751-CFCA942B-2862-49B7-B06B-CEF317DF73A9Q34125127-EB1B3C84-87C5-4DF7-A0B0-F9DC65F3BB42Q34341789-8C477400-74A0-4340-8786-FC16006F8352Q34653072-A5CD4F81-773D-49B0-9A2C-1E783EEC3568Q34717036-42C84C17-0E96-4C7E-BA3D-F76073C9E974Q34785533-0DFE0596-12A7-4DF8-A70F-45B5E30ACEB3Q35006424-7DF104E8-5A78-4FA2-A5E0-1037F573FCE2Q36035012-16A5EF7A-9F09-46FE-A000-0617F2D2BA3AQ36228730-08E55F6D-D17F-41A4-84C2-BB000C593D51Q36228933-52677128-9CAC-488A-86BC-048DBB3791FDQ36228960-AFEC1D58-303D-465E-A785-81C719DFEB24Q36354700-64FE2EDB-9528-4B52-843B-709F9CE25D22Q36784106-6FC929D2-339A-4DF3-85A4-4931A1B4970CQ36805062-DD308C93-26A6-4A5A-BBCE-0EACB7D5CB4FQ37061815-F9FE3C45-A3C7-4868-81AE-967F2A37D4ECQ37241258-A0B8A11A-AAB6-4E46-B9DE-170883F3E338Q37384724-83946354-E07F-4703-BF99-F78B90082DFBQ37559651-37C2B855-672A-4392-8DF2-A27A101E657CQ37580131-CC45BB4E-194A-4543-B973-41608BC1AF29Q37584248-7037D00C-3F4E-4BE3-AC76-FA5EBD8296E8Q37666787-F64ED831-7810-4EB4-9494-6B8DB5AF2947Q37710890-27EB6F0C-FF32-4FF4-8016-B4C88DDA5384Q37736208-C1487031-E925-481A-8370-F0EB7EE98C84Q37771945-EBF9B9B2-6C2D-4B34-A16E-5B94F4871E89Q37948951-C5C99903-3023-4185-8C02-492CEE6788C8Q38774777-0B00671E-A5F3-4724-92F6-2E3A5A5CA75BQ39576316-93BE6246-8548-46C1-942D-C35A8D9B9DFBQ39628533-5BC07C1F-992F-4BBF-A947-AFB050565B45Q40103874-2D305DAF-73A8-4401-A36C-2452CAFC906EQ40210840-390EA298-EAE6-455A-8469-93795A5187FAQ40230207-A7788CA7-B53F-49AC-8F55-EA29BC77DA93Q40408372-F9499505-DC64-4A9A-BB38-971D9C3BAB01Q40446857-DD4EF4CA-124C-4468-938C-30D5480DD358
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Cevayir Coban
@ast
Cevayir Coban
@en
Cevayir Coban
@es
Cevayir Coban
@nl
type
label
Cevayir Coban
@ast
Cevayir Coban
@en
Cevayir Coban
@es
Cevayir Coban
@nl
prefLabel
Cevayir Coban
@ast
Cevayir Coban
@en
Cevayir Coban
@es
Cevayir Coban
@nl
P106
P31
P496
0000-0002-4467-7799